Risks of Melatonin Supplementation
Melatonin is generally safe for short-term use with few serious adverse effects reported, but concerns exist regarding product purity, long-term safety data gaps (especially in children/adolescents), and specific risks in certain populations including those taking warfarin, patients with epilepsy, women of reproductive age, and individuals with glucose intolerance. 1
Common Adverse Effects
The most frequently reported side effects of melatonin include:
- Headaches (including morning headaches)
- Somnolence/daytime sleepiness
- Gastrointestinal upset (nausea)
- Dizziness
- Nightmares and abnormal dreams 2, 3
These effects are generally mild and often remit spontaneously. However, recent pharmacovigilance data from WHO-VigiBase identified additional potential safety signals including accidents and injuries, falls, nightmares, and abnormal dreams when compared to all other drugs 4.
Cardiovascular Concerns
Emerging evidence suggests potential cardiac rhythm disturbances:
- Atrioventricular block and ventricular arrhythmias have been reported in case reports, with complete resolution after melatonin discontinuation 5
- Hypotension and hypertension have been documented, particularly at higher doses 1
These cardiovascular effects warrant caution, though the mechanisms remain unclear and may involve melatonin receptor effects, pharmacokinetic variability, or genetic predisposition 5.
Metabolic and Endocrine Effects
Glucose intolerance has been demonstrated in healthy women following acute melatonin administration 1. This is particularly concerning for:
- Patients with diabetes or prediabetes
- Women of reproductive age
Concerns about effects on growth hormone regulation (at 10 mg doses) and reproductive function/development (at 3 mg doses) persist, though one study found no significant differences in pubertal development (Tanner stages) among children using melatonin (mean ~3 mg) over approximately 3 years 1.
Drug Interactions and Special Populations
Exercise caution or avoid melatonin in:
- Patients taking warfarin: Multiple case reports to WHO suggest potential interactions 1
- Patients with epilepsy: Case reports indicate possible exacerbation 1
- Patients with depression: Associated with increased depressive symptoms 1
- Patients with alopecia areata: May exacerbate condition at higher doses 1
Product Quality and Dosing Issues
A critical concern is that melatonin is regulated as a dietary supplement in the US/Canada (not FDA-approved medication), leading to:
- Unreliable purity and potency across preparations 1, 2
- Inconsistent stated doses on labels 1
- Variable bioavailability between formulations 2
Only products with United States Pharmacopeial Convention Verification can be considered most reliable 1, 2.
Pediatric Considerations
While no serious adverse events were detected in long-term follow-up studies of children (up to 4 years with doses up to 10 mg), rigorous long-term safety data remain scarce 1. The National Academy of Sciences specifically recommends caution in children/adolescents and women of reproductive age 1.
Caregivers frequently express concerns about:
- Growth hormone regulation effects
- Reproductive development impacts
- Long-term neurodevelopmental consequences
These concerns persist despite limited evidence of harm in available studies 1.
Long-Term Safety Data Gap
Studies addressing long-term effects are scarce. A 28-day trial in healthy male adults (10 mg) showed no adverse effects on sleep, clinical laboratory examinations, or subjective events 1. A meta-analysis of controlled trials (≤3 months duration) reported few adverse events 1. However, data beyond several months remain limited, particularly in vulnerable populations 6.
Dosing Context
Most adverse effects at higher doses (≥10 mg) exceed typical chronobiotic doses (0.5-5 mg). Effects reported at higher doses may occur at lower doses in patients with preexisting conditions 1.
Clinical Implications
Despite these risks, the 2015 American Academy of Sleep Medicine guidelines note that melatonin is "associated with a lack of reported serious adverse effects" in general use 1. The 2023 AASM RBD guideline states melatonin has "few side effects" compared to alternatives like clonazepam 2.
However, the 2017 AASM insomnia guideline suggests NOT using melatonin for sleep onset or maintenance insomnia (2 mg doses in older adults), citing very low quality evidence for efficacy 7. This reflects insufficient benefit rather than safety concerns per se.
The benefit-harm ratio remains uncertain due to limited high-quality long-term data, particularly in children, adolescents, and special populations 1.